References
- Coronavirus | 42Percent of patients in India between 21 and 40 years. (2020). India:
- Shinghal, T. (2020). A Review of Coronavirus Disease- 2019 (COVID-19). Nature Public Health Emergency Collection, 281-286.
- Edward Livingston, K. B. (2020). Coronavirus Disease 2019 (COVID-19) in Italy. Jama Network.
- Statista. (2020). Coronavirus (COVID-19) death rate in Italy as of October 6, 2020, by gender and age group. Retrieved from Italy:
- Erin K. Stokes, M., corresponding author,* Laura D. Zambrano, PhD,* Kayla N. Anderson, PhD, Ellyn P. Marder, DrPH, Kala M. Raz, MPH, Suad El Burai Felix, MPH, Yunfeng Tie, PhD, and Kathleen E. Fullerton, MPH. (2020). Coronavirus Disease 2019 Case Surveillance. Retrieved from United States:
- Times, T. N. Y. (2020). Does Covid-19 Hit Women and Men Differently? U.S. Isn't Keeping Track.
- Graziano Onder, G. R., Silvio Brusaferro. (2020). Case- Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. Jama Network.
- Timothy R. Abbott, G. D., Yanxia Liu, Xueqiu Lin, Laine Goudy, Leiping Zeng, Augustine Chemparathy, Stephen Chmura, Nicholas S. Heaton, Robert Debs, Tara Pande, Drew Endy, Marie La Russa, David B. Lewis, Lei S. Qi. (2020). Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza. bioRxiv. Worldometer.
- Konwarh, R. (2020). Can CRISPR/Cas Technology Be a Felicitous Stratagem Against the COVID-19 Fiasco? Prospects and Hitches. Frontiers in Molecular Biosciences.
- Zhi, Z. L. X. B. X. Z. (2020). The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. National Library of Medicine, 145-151.
- Rai, D. (2020). Young Indians comprise more than half of confirmed Covid-19 cases. New Delhi:
- Zunyou Wu, M., Jennifer M. McGoogan. (2020). Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. Jama Network.
- Saeid Chekani-Azar, E. G. M., Mastewal BIRHAN and Mahshad YOUSEFI. (2020). CRISPR/Cas9 gene editing technology and its application to the coronavirus. Journal of Life Science and Biomedicine.
- Samarasinghe, D. A., Nalawansha, Kusal T. G. (2020). Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19. ACS Publications, 790-800.
Cite this article
-
APA : Umair-Ul-Hassan., Khan, R. M. A., & Shafiq-Ur-Rehman. (2020). Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries. Global Drug Design & Development Review, V(I), 25-32. https://doi.org/10.31703/gdddr.2020(V-I).03
-
CHICAGO : Umair-Ul-Hassan, , Rana Muhammad Awais Khan, and Shafiq-Ur-Rehman. 2020. "Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries." Global Drug Design & Development Review, V (I): 25-32 doi: 10.31703/gdddr.2020(V-I).03
-
HARVARD : UMAIR-UL-HASSAN., KHAN, R. M. A. & SHAFIQ-UR-REHMAN. 2020. Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries. Global Drug Design & Development Review, V, 25-32.
-
MHRA : Umair-Ul-Hassan, , Rana Muhammad Awais Khan, and Shafiq-Ur-Rehman. 2020. "Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries." Global Drug Design & Development Review, V: 25-32
-
MLA : Umair-Ul-Hassan, , Rana Muhammad Awais Khan, and Shafiq-Ur-Rehman. "Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries." Global Drug Design & Development Review, V.I (2020): 25-32 Print.
-
OXFORD : Umair-Ul-Hassan, , Khan, Rana Muhammad Awais, and Shafiq-Ur-Rehman, (2020), "Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries", Global Drug Design & Development Review, V (I), 25-32
-
TURABIAN : Umair-Ul-Hassan, , Rana Muhammad Awais Khan, and Shafiq-Ur-Rehman. "Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries." Global Drug Design & Development Review V, no. I (2020): 25-32. https://doi.org/10.31703/gdddr.2020(V-I).03